Polarean’s Xenon MRI to Feature at ATS 2024 Conference and Respiratory Innovation Summit

DURHAM, NC and LONDON, May 08, 2024-- Polarean (AIM: POLX), a leader in the commercial stage of advanced magnetic resonance imaging (MRI) for lungs, has been selected to feature and present a poster at the American Thoracic Society’s (ATS) 2024 Respiratory Innovation Summit (RIS). This selection underscores the recognition of Polarean's XENOVIEW technology by lung specialists and pulmonary drug developers. The summit will be held on May 17th-18th in San Diego, CA, at the Manchester Grand Hyatt San Diego.

The Respiratory Innovation Summit is a prominent event in pulmonary medicine that brings together innovators, investors, clinicians, and advocacy groups. This gathering typically attracts over 275 global leaders from various sectors of the respiratory industry, including startups, venture capital, government, academia, and clinical practice.

Following the discussions at the Respiratory Innovation Summit, Polarean looks forward to engaging further with the pulmonary medicine community at the 2024 ATS International Conference from May 19th to 22nd. Visitors can interact with Polarean's executive team at booth #2813, including Chief Executive Officer Christopher von Jako, PhD; Chief Commercial Officer Alex Dusek; and VP of Technology & Applications Kiarash Emami, PhD. They will provide detailed insights into Polarean’s mission to transform pulmonary medicine through direct lung ventilation visualization and discuss future collaborations and innovations in lung imaging.

This year marks a significant milestone for Xenon MRI research, with a record number of 33 presentations from 10 different sites, covering various categories such as asthma, bronchopulmonary dysplasia, COPD, COVID-19, cystic fibrosis, lung cancer resection, radiation-induced lung injury, pulmonary arterial hypertension, and thoracic insufficiency syndrome.

Polarean’s CEO, Christopher von Jako, PhD, expressed the importance of the Respiratory Innovation Summit and the ATS annual conference as crucial platforms to highlight their Xenon MRI technology. These events are viewed as excellent opportunities to increase awareness of their technology among clinicians, regulators, investors, and potential pharmaceutical partners. The growing number of Xenon MRI posters and presentations reflects significant progress in understanding and enthusiasm for this technology and its potential benefits across various therapeutic areas.

The following are details of the presentations:
- "Hyperpolarized 129Xe MRI: What Additional Information Does It Provide?" on May 18, 2024, at 3:10 PM in Room 6D.
- "Quantifying the Impact of Cannabis Smoking in Lungs of Young Adults Using CT and Xe MRI" on May 19, 2024, at 9:15 AM in Room 6E.
- "Six-month Longitudinal Changes in 129-XE and HRCT Imaging Metrics Tend to Associate With On-study COPD Exacerbations" on May 19, 2024, at 9:15 AM in Room 6E.
- "Advanced 4D Hyperpolarized Gas Imaging of Ventilation and Dissolved Gas Biomarkers in COPD" on May 19, 2024, at 9:15 AM in Room 6E.
- "3-month Change in Hyperpolarized Xe MRI Membrane Uptake Predicts 6-month Change in Lung Function in Patients With Idiopathic Pulmonary Fibrosis" on May 19, 2024, at 11:30 AM in Area H.
- "Using Xenon MRI to Evaluate the Trajectories of Idiopathic Pulmonary Fibrosis" on May 19, 2024, at 2:15 PM in Room 33A-C.
- "Combining Hyperpolarized Xe MR Imaging and Spectroscopy to Estimate Pulmonary Vascular Resistance" on May 19, 2024, at 3:39 PM in Room 6D.
- "Magnetic Resonance Imaging Ventilation Phenotypes of Severe Asthma" on May 19, 2024, at 3:39 PM in the Pacific Ballroom.
- Other presentations follow across May 20th to May 22nd in various sessions and locations at the San Diego Convention Center.

Polarean is dedicated to revolutionizing pulmonary medicine with its innovative imaging solutions. Their hyperpolarized Xenon MRI technology, FDA-approved in the U.S., provides a non-invasive and radiation-free method for visualizing lung function, offering significant potential benefits for over 500 million patients globally suffering from chronic respiratory diseases. Polarean continues to push the boundaries of medical imaging technology from its offices in Durham, NC, and London, UK.

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!